NeoprediX B1 algorithm
Diagnostic TestRe-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
NCT Number: NCT05121311
Due to actual standard of neonatal care bilirubin is monitored in neonates several times after birth to avoid hyperbilirubinemia. As the peak is often one or two days after discharge from hospital a more precise predication than the actual one is desirable to avoid needlessly follow-ups. The precision of an algorithm to predict bilirubin values 24-48h into the future is evaluated in this study.
Looking for future studies?
Notify MeUp to 72 hour
All sexes
Observational
KUNO Kinderklinik St. Hedwig, Regensburg, Germany
Neonatal jaundice is common and mostly transient without need for intervention. To identify infants at risk of bilirubin toxicity, bilirubin is measured several times after birth and before discharge home. As the peak bilirubin concentrations are reached at days 4-6 after birth, and most infants are discharged home around 48 hours after birth, parents are often asked to return to hospital one or two days after discharge with their newborn baby to have the bilirubin value checked in order to prevent that hyperbilirubinemia requiring treatment is not missed. A precise prediction of the course of bilirubin values based on the measurements done during the initial hospital stay after birth would be desirable to avoid unnecessary follow ups (both for the families and the health care system).
This study aims to evaluate the precision of the NeoprediX B1 algorithm. This algorithm predicts bilirubin values 24-48h into the future based on preceding values and some clinical variables. Five different scenarios will be explored, differing in the type, number and timepoints of measurements used for the prediction as well as the timepoint that is to be predicted.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
Time frame: 8 hours to 144 hours after birth
Precision of the bilirubin value calculated by the NeoprediX B1 algorithm compared to the value measured by the center
NeoPredix AG
Industry
Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm - Prospective Observational Study -
Acronym: Bili-PrediX1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06921330
ABO Incompatibility, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Karabük, Karabük Province, Turkey (Türkiye)
View Trial DetailsNCT06209489
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hyperbilirubinemia
Karabük, Turkey (Türkiye)
View Trial DetailsNCT05692648
Bilirubinemia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Konya, Selcuklu/Konya, Turkey (Türkiye)
View Trial DetailsNCT06837935
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hyperbilirubinemia
New Taipei City, Taiwan
View Trial Details